Literature DB >> 2462132

Clinical applications of antiandrogens.

M Namer1.   

Abstract

Antiandrogens, substances that prevent androgens from expressing their activity at target cells, play an important role in the treatment of prostate cancer. The most frequently used substances have either a steroidal structure (cyproterone acetate) or a non-steroidal structure (Flutamide or Anandron). Antiandrogens have been tested both alone and in combination with treatments aimed at inhibiting testicular secretion (castration, LH-RH analogs), thereby producing complete blockade of androgen secretion and action. Patients treated by such combination protocols have often shown an improvement in the percentage of remissions and, less often, improvement in survival. Administration of antiandrogens improves the clinical symptoms of patients with benign prostatic hypertrophy, but the exact mechanism of their action requires further investigation. Cutaneous manifestations due to hyperandrogenicity (hirsutism, alopecia, acne) have also been improved by cyproterone acetate, which is often given together with estrogens (reversed sequential regime), by spironolactone or topically applied products. Finally, antiandrogens have been successfully used to treat breast cancer in men, early puberty, hypersexuality and sexual deviations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462132     DOI: 10.1016/0022-4731(88)90023-4

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  3 in total

Review 1.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

2.  Why do winners keep winning? Androgen mediation of winner but not loser effects in cichlid fish.

Authors:  Rui F Oliveira; Ana Silva; Adelino V M Canário
Journal:  Proc Biol Sci       Date:  2009-03-11       Impact factor: 5.349

3.  Male hormone-interfering drugs and meningioma development.

Authors:  Laura Giraldi; Jørgen Vinsløv Hansen; Jan Wohlfahrt; Mads Melbye; Kåre Fugleholm; Tina Nørgaard Munch
Journal:  Neurooncol Adv       Date:  2019-11-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.